Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04491084 · ClinicalTrials.gov registry record · Phase 1
FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy
A Phase 1 study, sponsored by Albert Einstein College of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT04491084: Clinical Trial Phase 1 study, sponsored by Albert Einstein College of Medicine.
NCT04491084 is a Phase 1 study that was terminated before completion, run by Albert Einstein College of Medicine. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04491084, a Phase 1 study, was terminated before completion, sponsored by Albert Einstein College of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to test a new way of treating the most common form of lung cancer. The investigators are testing a combination of radiotherapy with two new forms of immunotherapy. This study is testing the safety and effectiveness of this treatment approach as compared to standard treatment options.
Primary Outcome
Death Any ≥ Grade 3 non-hematological toxicity, with the following exceptions: Grade 3 alopecia, vitiligo, or endocrinopathies controlled by hormone replacement therapy Grade 3 nausea that resolves to ≤ grade 2 with or without treatment within 72 hours Grade 3 vomiting and diarrhea that resolves to ≤ grade 2 with or without treatment within 72 hours Grade 3 fatigue that resolves to ≤ grade 2 within 5 days Grade 3 hypertension in the absence of maximal medical therapy Grade 3 adverse event of t
Interventions
- RADIATION SBRT
- DRUG FLT3 Ligand (CDX-301)
- BIOLOGICAL anti-CD40 antibody (CDX-1140)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-01-01 |
| Est. Completion | 2022-08-18 |
| Phase | Phase 1 |
Why NCT04491084 stopped before completion
NCT04491084 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 3 interventions - of which SBRT is the first listed.
NCT04491084 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04491084 about?
NCT04491084 is a clinical study titled "FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy". The purpose of this study is to test a new way of treating the most common form of lung cancer. The investigators are testing a combination of radiotherapy with two new forms of immunotherapy. This study is testing the safety and effectiveness of this treatment approach as compared to standard treat...
What is the current status of trial NCT04491084?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2021-01-01. Estimated completion is 2022-08-18.
What interventions are being tested in trial NCT04491084?
The interventions under investigation include: SBRT (RADIATION), FLT3 Ligand (CDX-301) (DRUG), anti-CD40 antibody (CDX-1140) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04491084?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04491084's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI